| Ytd | -14.38% | |
| 1y | -14.94% |
| Open | 1.33 | Prev Close | 1.33 | Low | 1.29 | High | 1.33 | Mkt Cap | 79.69M |
| Vol | 258.49K | Avg Vol | 655.28K | EPS | -0.63 | P/E | N/A | Forward P/E | -1.25 |
| Beta | 0.34 | Short Ratio | 10.99 | Inst. Own | 7.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 1.37 | 200-d Avg | 1.47 | 1yr Est | 12.63 |
MAIA News
New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.13) per share which missed the analy
Anna Edwards, Guy Johnson and Adam Linton break down today's key themes for analysts and investors o
90.5% interim disease control rate (DCR) observed with combination therapyInitial Part C efficacy ob
90. 5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (G
Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recogniz
Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing wi
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-s
Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Ap
Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Ap
Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an
CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", t
THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in
CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, t
New York, May 18, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm w
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.14) per share which beat the analyst
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control,
Strong participation in recent $33 million common stock offering highlights investor confidence in l
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026
Potential breakthrough therapeutic targets $50B+ global immunotherapy market 1 CHICAGO, March 31, 20
New York, March 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst
US stocks down amid Iran-US conflict. Tehran closed Strait of Hormuz & warned of firing on vesse
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 900 points on Tues
Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported bet
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biop
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical succ
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biop
Key milestone achieved as Company advances clinical program to full approval trial of ateganosine se
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countr
Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO
MAIA's Board of Directors authorizes holdings of up to 90% of the Company's liquid assets in
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.18) per share which beat the analyst